disorder

(redirected from Myeloproliferative disorders)
Also found in: Dictionary, Thesaurus, Medical, Legal.

disorder

[dis′ȯrd·ər]
(crystallography)
Departures from regularity in the occupation of lattice sites in a crystal containing more than one element.
References in periodicals archive ?
9) disorders, ($) Myeloproliferative disorder 3/15 (20.
FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12; 13)(p13; q12) translocation.
They most commonly arise in patients previously diagnosed with a myeloproliferative disorder, but they can be the presenting sign of cancer or even precede the onset of hematogenous disease by months to years.
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders," Blood, vol.
Horses with myeloproliferative disorders in general do not show breed or age predisposition and, apparently, males seem to be more often affected (TAINTOR, 2012).
In vivo Hydroxyurea therapy has been suggested to increase the risk of acute leukemia for the patient with Myeloproliferative disorder (18,25) but its carcinogenic potential in other clinical settings is much less compelling and no adults up to 9 years of drug exposure have had secondary leukemia develop (26) Moreover, quantative analysis of acquired DNA mutations suggest that mutagenic potential hydroxyl urea for patient with Sickle Cell Disease is low (27) however, anecdotes of Malignancy or Myelodysplasias in patient with Sickle Cell Disease on Hydroxyurea are emerging (24,28) consideration of its carcinogenic potential should be given, because more and more sickle cell anemia may be treated with Hydroxyurea and pathology should be altered to this potential.
The causes of thrombocytosis could be multiple such as myeloproliferative disorders ,reactive thrombocytosis, Post splenectomy and hyposplenism.
Congenital leukaemia and the neonatal myeloproliferative disorders associated with Down's syndrome.
Hematologic malignancies can be categorized as myeloid neoplasms, lymphoid neoplasms (leukemias and lymphomas), and myeloproliferative disorders.
The concept of myeloproliferative disorders (MPD) was first described by William Dameshek in 19511.
A prospective evaluation of primary myeloproliferative disorders.
To establish a diagnosis of ET, reactive causes of thrombocytosis should be absent and other chronic myeloproliferative disorders should be ruled out (1).